ArticleACS omega2026
Research on Injectable Hydrogel GelMA-HA-CGF Loaded with Dental Pulp Stem Cells (DPSC) for Periodontal Regeneration.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we aimed to construct an injectable hydrogel composed of gelatin methacryloyl/hyaluronic acid (GelMA-HA) and combine it with lyophilized concentrated growth factors (CGF) and dental pulp stem cells (DPSC) to promote the process of periodontal regeneration. We confirmed that bioactive lyophilized CGF can be anchored to hydrogels by Schiff base imine bonding, thereby achieving effective sustained release of various growth factors in the inflammatory microenvironment of periodontal bone destruction. Meanwhile, this hydrogel can provide a 3D cell growth microenvironment to improve the survival rate of dental pulp stem cells. GelMA-HA-CGF-DPSCs exhibit remarkable ability to promote cell proliferation and differentiation as well as excellent biocompatibility. In vitro experiments demonstrated that this system can increase alkaline phosphatase activity, enhance osteogenic mineralization capacity, and significantly upregulate the expression of osteogenesis-related genes and proteins. In the rat alveolar bone defect model, the experimental group significantly facilitated regeneration of periodontal bone. These findings suggest that this injectable composite material has the potential to overcome the limitations of CGF applications and stem cell injections. Specifically, through the chemotactic effects of growth factors and intercellular interactions, endogenous stem cells can also attract endogenous stem cells. Serving as a scaffold structure, it creates an osteogenic microenvironment and provides a space for bone regeneration. Moreover, its injectability and fluidity can achieve minimally invasive periodontal treatment in a noninvasive manner. The findings of this study are expected to provide valuable insights and references for the clinical translational repair treatment of periodontal bone defects caused by periodontitis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.